IBEX 35
10.889,30 +17,30 (+0,16%) Euro Stoxx 50
4.917,56 +26,95 (+0,55%) Dólar/Euro
1,0806 +0,0079 (+0,73%) Petróleo Brent
84,14 +0,47 (+0,56%) Oro
2.305,70 -3,90 (-0,17%) Bitcoin EUR
55.794,46 +1.398,81 (+2,57%)
TransCode Therapeutics, Inc. (RNAZ)
Antes de la apertura:
TransCode Therapeutics, Inc.
6 Liberty Square
Suite 2382
Boston, MA 02109
United States
857 837 3099
https://www.transcodetherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 10
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Thomas A. Fitzgerald M.B.A. | Interim CEO, CFO, President, VP of Administration & Director | 358,14k | N/A | 1952 |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Executive Chairman of the Board | 102,5k | N/A | 1959 |
| Dr. Zdravka Medarova Ph.D. | Co-Founder & Chief Scientific Officer | N/A | N/A | 1975 |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board | N/A | N/A | 1962 |
| Ms. Susan Duggan M.B.A., R.N. | Senior Vice President of Operations | N/A | N/A | N/A |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer | N/A | N/A | 1952 |
Descripción
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de TransCode Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
